Karen Daily, D.O.
Clinical Professor
Department:
MD-HEMATOLOGY/ONCOLOGY
Business Phone:
(352) 273-7832
Business Email:
karen.daily@medicine.ufl.edu
About Karen Daily
Karen C. Daily, DO, is a professor of medicine in the Division of Hematology and Oncology at the University of Florida College of Medicine.
Dr. Daily earned her Bachelor of Science from The Ohio State University and her medical degree from Lake Erie College of Osteopathic Medicine. She completed residency at Wyckoff Heights Medical Center in internal medicine and fellowship at UF in hematology and oncology. She served three years active duty in the United States Army.
Dr. Daily is a clinically-based investigator and educator with a focus in breast cancer. She is board-certified in internal medicine, medical oncology, and hematology. She is a member of the American Society of Clinical Oncology and Co-Chair of the Epidemiology and Prevention Item Writing Task Force. Dr. Daily serves as the Division Education Director and is the recipient of multiple teaching awards including the Fellowship Positive Impact Award.
Dr. Daily founded the High Risk Program, within UF Health Breast Center, that identifies women at above-average risk of developing breast cancer and offers prevention and early detection strategies. Dr. Daily serves as Associate Medical Director of the Medical Oncology Clinic. She is committed to resolving access to care barriers in disadvantaged populations and passionate about improving the efficiency of the health care system.
As the Breast Cancer Disease Site Group’s Research Leader, Dr. Daily is responsible for the UF Health Breast Center’s clinical trials portfolio. This role involves both selection of cooperative group and industry protocols that fit the needs of UF Health’s patient population and collaborative efforts with colleagues across multiple disciplines to develop novel institutional initiated trials. She is an active member of the National Surgical Adjuvant Bowel and Breast Project (NSABP)/NRG Oncology and has served as Co-Chair of the Rare Breast Cancer Committee.
Teaching Profile
Courses Taught
2017-2018
MDT7200 Elect Top/Medicine
2016,2018
MDC7200 Medicine Clerkship
2018
MDC7203 Senior Medicine Clerk
2018
MDC6001 Intro Clin Practice
Clinical Profile
Specialties
- Cancer
- Hematology and Oncology
Areas of Interest
- Breast Cancer
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-3218-9739
Publications
Academic Articles
2025
Erratum: Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
JCO precision oncology.
9
[DOI] 10.1200/PO-25-00369.
[PMID] 40403212.
2025
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy.
JACC. CardioOncology.
7(2):110-121
[DOI] 10.1016/j.jaccao.2024.10.012.
[PMID] 39967196.
2024
Implementation of a pharmacogenetic panel-based test for pharmacotherapy-based supportive care in an adult oncology clinic.
Clinical and translational science.
17(7)
[DOI] 10.1111/cts.13890.
[PMID] 39046302.
2024
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms
JCO Precision Oncology.
(8)
[DOI] 10.1200/po-24-00406.
2023
Bilateral primary breast Burkitt’s lymphoma in pregnancy.
BMJ case reports.
16(1)
[DOI] 10.1136/bcr-2022-251896.
[PMID] 36653041.
2023
Clinical characteristics, prognostic factors, and long-term outcomes associated with epithelial malignancies of the thymus: A 20-year single-institution experience.
Cancer reports (Hoboken, N.J.).
6(3)
[DOI] 10.1002/cnr2.1750.
[PMID] 36369906.
2023
Immune-mediated herb-induced liver injury: a potential association with herbal artemisinin use as supported by the updated RUCAM.
BMJ case reports.
16(5)
[DOI] 10.1136/bcr-2022-251852.
[PMID] 37142282.
2023
Systemic absorption of intrathecal methotrexate.
BMJ case reports.
16(4)
[DOI] 10.1136/bcr-2022-254027.
[PMID] 37072302.
2022
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician’s Choice for Patients With Residual Triple-Negative Breast Cancer
Journal of Clinical Oncology.
40(4):345-355
[DOI] 10.1200/jco.21.01657.
2022
Does definitive local therapy have a role in select HER2+ de novo metastatic breast cancer patients treated with dual anti-HER2 blockade?
Breast Cancer Research and Treatment.
191(2):375-383
[DOI] 10.1007/s10549-021-06440-z.
2022
Endocrine adherence in male versus female breast cancer: a seer-medicare review.
Breast cancer research and treatment.
192(3):491-499
[DOI] 10.1007/s10549-022-06536-0.
[PMID] 35142938.
2021
Acinic Cell Carcinoma of the Breast: Report of a Case With Immunohistochemical and Next-Generation Sequencing Studies
International Journal of Surgical Pathology.
29(8):882-886
[DOI] 10.1177/10668969211008508.
2021
Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer.
The oncologist.
26(5):362-e724
[DOI] 10.1002/onco.13689.
[PMID] 33512054.
2021
ASO Visual Abstract: A 5-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1-4N1-3M0 Breast Cancer
Annals of Surgical Oncology.
[DOI] 10.1245/s10434-021-10648-0.
[PMID] 34655351.
2021
Chemotherapy education: current practices of oncology nurses counseling patients.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
29(12):7323-7328
[DOI] 10.1007/s00520-021-06308-4.
[PMID] 34041616.
2021
Epidemiology of De Novo Metastatic Breast Cancer.
Clinical breast cancer.
21(4):302-308
[DOI] 10.1016/j.clbc.2021.01.017.
[PMID] 33750642.
2021
Five-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1-4N1-3M0 Breast Cancer.
Annals of surgical oncology.
28(10):5775-5787
[DOI] 10.1245/s10434-021-10551-8.
[PMID] 34365563.
2021
Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.
The oncologist.
26(10):825-e1674
[DOI] 10.1002/onco.13853.
[PMID] 34101295.
2021
The association between cognitive impairment and breast and colorectal cancer screening utilization.
BMC cancer.
21(1)
[DOI] 10.1186/s12885-021-08321-6.
[PMID] 33975576.
2020
A case for Tamoxifen with ovarian function suppression.
Breast cancer research and treatment.
183(1):241-242
[DOI] 10.1007/s10549-020-05766-4.
[PMID] 32601972.
2020
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
JAMA oncology.
6(9):1410-1415
[DOI] 10.1001/jamaoncol.2020.2295.
[PMID] 32644110.
2020
Concomitant Radiation Recall Dermatitis and Organizing Pneumonia following Breast Radiotherapy: A Case Report.
Case reports in oncology.
13(2):875-882
[DOI] 10.1159/000508493.
[PMID] 32884534.
2020
How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.
Clinical pharmacology and therapeutics.
108(3):557-565
[DOI] 10.1002/cpt.1912.
[PMID] 32460360.
2020
Outcomes of primary endocrine therapy in elderly women with stage I-III breast cancer: a SEER database analysis.
Breast cancer research and treatment.
180(3):819-827
[DOI] 10.1007/s10549-020-05591-9.
[PMID] 32172303.
2019
Projected clinical benefit of surveillance imaging for early detection and treatment of breast cancer metastases.
The breast journal.
25(1):75-79
[DOI] 10.1111/tbj.13153.
[PMID] 30548515.
2018
Bevacizumab Eligibility in Patients with Metastatic and Recurrent Cervical Cancer: A Retrospective Review.
Clinical Medicine Insights. Oncology.
12
[DOI] 10.1177/1179554918779587.
[PMID] 29887734.
2018
Epidemiological, Clinical, and Histopathological Features of Breast Cancer in Haiti.
Journal of global oncology.
4:1-9
[DOI] 10.1200/JGO.17.00135.
[PMID] 30241242.
2018
The Toxicity of Time.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
36(3):300-301
[DOI] 10.1200/JCO.2017.74.7907.
[PMID] 29016227.
2018
Tumour lysis syndrome following eribulin for metastatic uterine leiomyosarcoma.
BMJ case reports.
11(1)
[DOI] 10.1136/bcr-2018-224576.
[PMID] 30573532.
2018
Women’s Health Curriculum for Medical Students.
Southern medical journal.
111(3):183-186
[DOI] 10.14423/SMJ.0000000000000783.
[PMID] 29505657.
2017
Gemcitabine-induced chronic systemic capillary leak syndrome.
BMJ case reports.
2017
[DOI] 10.1136/bcr-2017-221068.
[PMID] 28855215.
2017
Stereotactic body radiation therapy for oligoprogression of metastatic disease from gastrointestinal cancers: A novel approach to extend chemotherapy efficacy.
Oncology letters.
13(3):1087-1094
[DOI] 10.3892/ol.2016.5540.
[PMID] 28454218.
2016
Development of a Breast Cancer Treatment Program in Port-au-Prince, Haiti: Experiences From the Field.
Journal of global oncology.
2(1):9-14
[DOI] 10.1200/JGO.2015.000364.
[PMID] 28717677.
2016
Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma.
Journal of gastrointestinal oncology.
7(2):173-80
[DOI] 10.3978/j.issn.2078-6891.2015.071.
[PMID] 27034783.
2015
Breast Cancer: Instructional Module
.
2015
Hepatoid Adenocarcinoma of the Colon
.
2015
Hepatoid adenocarcinoma of the colon.
BMJ case reports.
2015
[DOI] 10.1136/bcr-2014-206222.
[PMID] 25883249.
2014
Common variable immunodeficiency syndrome in an adult.
Lancet (London, England).
383(9920)
[DOI] 10.1016/S0140-6736(14)60415-3.
[PMID] 24607101.
2014
Controversies in Adjuvant Chemotherapy
.
2014
Preventing breast cancer recurrence through a tailored lifestyle intervention: The MyLIFE (My Lifestyle Intervention with Food and Exercise) Trial Rationale and Study Design
.
4(5):183-190
2013
Peers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
31(10):1371-2
[DOI] 10.1200/JCO.2013.48.8650.
[PMID] 23423749.
Grants
May 2025
ACTIVE
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
Apr 2025
ACTIVE
LoTam: a Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Jan 2025
ACTIVE
A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigators Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy
Role: Principal Investigator
Funding: LILLY USA
Jan 2025
ACTIVE
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via GENENTECH INC
Jan 2025
ACTIVE
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Role: Principal Investigator
Funding: LILLY USA
Jan 2025
– Apr 2025
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via GENENTECH INC
Dec 2024
ACTIVE
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent
and in Combination with Pembrolizumab Versus Treatment of Physicians Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
Role: Principal Investigator
Funding: MERCK SHARP & DOHME
Jul 2024
ACTIVE
Cardiovascular Adverse Events Related to Aromatase Inhibitors in Breast Cancer
Role: Co-Investigator
Funding: FL BREAST CANCER FOU
Jun 2024
ACTIVE
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of
Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Role: Principal Investigator
Funding: ASTRAZENECA UK
Apr 2024
– Mar 2025
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Role: Principal Investigator
Funding: GILEAD SCIENCES
Nov 2023
– Apr 2024
A standalone qualitative interview study among EMBER-3 participants: A patient experience study
Role: Principal Investigator
Funding: CLARIVATE ANALYTICS
via ELI LILLY AND CO
Oct 2023
ACTIVE
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
via ASTRAZENECA UK
Aug 2023
– Feb 2025
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Jul 2023
ACTIVE
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Jun 2023
– Feb 2025
OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Jun 2023
– Sep 2024
OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY
Jun 2023
ACTIVE
High Intensity Interval Training: Optimizing Exercise Therapy to Mitigate Cardiovascular Disease Risk Following Breast Cancer Chemotherapy
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Jun 2023
– May 2025
Novel Methods of Chemo-sensitizing Low-proliferative Disseminated Tumor Cells in Triple Negative Breast Cancer
Role: Principal Investigator
Funding: UNIV OF SOUTHERN CALIFORNIA
via NATL INST OF HLTH NCI
Jul 2022
– Jun 2023
Risk of adverse cardiovascular events in breast cancer patients receiving systemic adjuvant therapy: impact of comorbidity burden
Role: Co-Investigator
Funding: FL BREAST CANCER FOU
May 2022
– Jul 2023
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor Positive, HER2 Negative Early Breast Cancer
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
via GENENTECH INC
Dec 2021
– Feb 2025
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Nov 2021
– Jan 2025
A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigators Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy
Role: Principal Investigator
Funding: LILLY USA
Sep 2021
ACTIVE
Combination Trastuzumab and Vaccine Therapy to Prevent Disease Recurrence in Locally Advanced HER2+ Breast Cancer
Role: Principal Investigator
Funding: MAYO CLINIC
via US ARMY MED RES ACQUISITION
Jul 2021
– May 2025
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
Jul 2021
– Dec 2024
Prospective Study of Early Markers of Cancer Treatment-Induced Cardiac Injury in Breast Cancer Patients
Role: Co-Project Director/Principal Investigator
Funding: FL BREAST CANCER FOU
Jun 2021
– May 2025
All-Extremity Exercise as a Novel Strategy for Optimizing Cardiovascular Function during Chemotherapy for Breast Cancer
Role: Co-Investigator
Funding: NATL INST OF HLTH NHLBI
Apr 2021
– Mar 2024
Optimizing the Population Representativeness of Older Adults in Cancer Trials
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Jan 2021
– Mar 2022
CDK 4/6 inhibitors use among metastatic breast cancer patients: Early discontinuation and management of adverse events
Role: Co-Investigator
Funding: PFIZER INC
Jun 2020
– Oct 2022
Novel Methods of Chemo-sensitizing Low-proliferative Disseminated Tumor Cells in Triple Negative Breast Cancer
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
May 2020
– Jan 2025
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via GENENTECH INC
Mar 2020
– Mar 2025
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via SYNDAX PHARMACEUTICALS
Feb 2020
ACTIVE
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive b
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Dec 2019
– Jan 2025
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via GENENTECH INC
Oct 2019
– Oct 2024
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
Jun 2019
ACTIVE
Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Mar 2019
ACTIVE
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
via NATL INST OF HLTH NCI
Mar 2019
– Feb 2025
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Mar 2019
– Feb 2025
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
via NATL INST OF HLTH NCI
Mar 2019
– Feb 2025
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Aug 2018
– Aug 2023
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Aug 2018
– Aug 2023
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
Role: Principal Investigator
Funding: SWOG CLINICAL TRIALS INITIATIVE
Apr 2018
– May 2019
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment withou
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Jan 2018
– Jan 2025
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Role: Principal Investigator
Funding: LILLY USA
Dec 2016
– Dec 2021
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Aug 2016
– Aug 2021
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Mar 2016
– Jun 2021
Early markers of subclinical pulmonary vascular radiation toxicity in breast cancer
Role: Co-Investigator
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Mar 2016
– Mar 2021
Novel strategies to target disseminated tumor cells in triple negative breast cancer
Role: Project Manager
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Jun 2015
– Jun 2017
Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Sep 2014
– Sep 2017
A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
via PUMA BIOTECHNOLOGY INC
Aug 2014
– Mar 2023
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer
Role: Principal Investigator
Funding: HOOSIER CANCER RESEARCH NETWORK
May 2014
– May 2017
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Docetaxel in Combination with 1-methyl-D-tryptophan (indoximod) in Metastatic Breast Cancer
Role: Principal Investigator
Funding: NEW LINK GENETICS
Mar 2014
– Mar 2021
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Mar 2014
– Feb 2019
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
Oct 2013
– Oct 2016
NSABP Biospecimen Discovery Project (DP-1)
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
via BREAST CANCER RESEARCH FOU
Mar 2013
– May 2019
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
via NATL INST OF HLTH NCI
Mar 2013
– Feb 2019
A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL TUMOR…
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
Jan 2012
– Feb 2019
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
via NATL INST OF HLTH NCI
Jan 2012
– Mar 2020
S1007, "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less"
Role: Principal Investigator
Funding: SOUTHWEST ONCOLOGY GROUP
via NATL INST OF HLTH
Jul 2005
– Jul 2017
NSABP B-38 A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubincin/Cyclophosphamide (YAC): Dose-Dense (DD) Doxorubincin/Cyclophosmide Followed by DD Paclitaxel (DD AC P):
Role: Principal Investigator
Funding: EASTERN COOP ONCOLOGY GROUP
via NATL INST OF HLTH
May 2005
– May 2017
NSABP Protocol B-35 – A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in SITU (DCIS) Undergoing Lumpectomy with Radiation Therapy
Role: Principal Investigator
Funding: EASTERN COOP ONCOLOGY GROUP
via NATL INST OF HLTH
Contact Details
Phones:
- Business:
- (352) 273-7832
Emails:
- Business:
- karen.daily@medicine.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100278
GAINESVILLE FL 32610